Immix Biopharma annual total assets
2020
2021
2022
2023
2024
2025
Immix Biopharma Total Assets Growth & History (IMMX)
Immix Biopharma's total assets was $104.8M for fiscal 2025.
View full Immix Biopharma company overviewImmix Biopharma annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $104.8M | $81.9M | +356.86% |
| 2024 | 2024-12-31 | $22.9M | $3.0M | +15.17% |
| 2023 | 2023-12-31 | $19.9M | $5.0M | +33.65% |
| 2022 | 2022-12-31 | $14.9M | −$3.3M | −18.05% |
| 2021 | 2021-12-31 | $18.2M | $17.7M | +3271.42% |
| 2020 | 2020-12-31 | $539,597 | — | — |
Immix Biopharma quarterly total assets
Q4.20
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $239.1M | $223.5M | +1429.31% |
| Q1 2026 | 2026-03-31 | $95.8M | $75.9M | +381.68% |
| Q4 2025 | 2025-12-31 | $104.8M | $81.9M | +356.86% |
| Q3 2025 | 2025-09-30 | $20.1M | −$5.1M | −20.13% |
| Q2 2025 | 2025-06-30 | $15.6M | −$13.2M | −45.78% |
| Q1 2025 | 2025-03-31 | $19.9M | −$14.5M | −42.09% |
| Q4 2024 | 2024-12-31 | $22.9M | $3.0M | +15.17% |
| Q3 2024 | 2024-09-30 | $25.1M | $2.7M | +11.87% |
| Q2 2024 | 2024-06-30 | $28.8M | $13.3M | +85.24% |
| Q1 2024 | 2024-03-31 | $34.3M | $21.1M | +159.98% |
| Q4 2023 | 2023-12-31 | $19.9M | $5.0M | +33.65% |
| Q3 2023 | 2023-09-30 | $22.5M | $5.1M | +29.20% |
| Q2 2023 | 2023-06-30 | $15.6M | −$3.5M | −18.45% |
| Q1 2023 | 2023-03-31 | $13.2M | −$6.8M | −34.00% |
| Q4 2022 | 2022-12-31 | $14.9M | −$3.3M | −18.05% |
| Q3 2022 | 2022-09-30 | $17.4M | — | — |
| Q2 2022 | 2022-06-30 | $19.1M | — | — |
| Q1 2022 | 2022-03-31 | $20.0M | — | — |
| Q4 2021 | 2021-12-31 | $18.2M | $17.7M | +3271.42% |
| Q4 2020 | 2020-12-31 | $539,597 | — | — |
Immix Biopharma total assets trends
Over the last five fiscal years, Immix Biopharma's total assets increased from $539,597 to $104.8M, a change of $104.3M. The latest reported quarter, Q2 2026, shows $239.1M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immix Biopharma source filings ↗